Trial Profile

A Phase 1, Open Label, Drug Interaction Study to Evaluate the Effect of ZYN002 on the Pharmacokinetics of CYP3A4, CYP2C19, CYP2C9, CYP2D6, CYP1A2, CYP2C8, and CYP2B6 Probe Substrates, and Valproate in Healthy Adult Participants

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bupropion (Primary) ; Caffeine (Primary) ; Cannabidiol (Primary) ; Dextromethorphan (Primary) ; Losartan (Primary) ; Midazolam (Primary) ; Omeprazole (Primary) ; Repaglinide (Primary) ; Valproic acid (Primary)
Indications DiGeorge syndrome; Epilepsy; Fragile X syndrome; Pervasive child development disorders
Focus Pharmacokinetics
Sponsors Harmony Biosciences

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com